Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Recruiting

Phase 2

Phase 3

ABBV-RGX-314Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Sponsor:

AbbVie

Code:

NCT04704921

Conditions

AMD

nAMD

Wet Age-related Macular Degeneration

wAMD

Wet AMD

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Not accepted

Interventions

ABBV-RGX-314

Ranibizumab (LUCENTIS®)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-15. This information was provided to ClinicalTrials.gov by AbbVie on 2025-08-20.